title: [New ESC guideline takes NOAK into account].
authors.forename: Katharina
authors.initials: K
authors.lastname: Arnheim
mesh_terms: D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use*; D019983:Guideline Adherence; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000145:classification* / Q000188:drug therapy*; D018570:Risk Assessment; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D014812:Vitamin K; D006493:Heparin; D000069552:Rivaroxaban